CF PharmTech, Inc. (HKG:2652)

Market Cap	9.40B
Revenue (ttm)	647.51M +1,338.4%
Net Income	29.75M
EPS	0.08
Shares Out	411.48M
PE Ratio	284.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	392,500
Average Volume	1,498,539
Open	22.30
Previous Close	22.32
Day's Range	22.00 - 23.56
52-Week Range	20.30 - 48.80
Beta	n/a
RSI	31.94
Earnings Date	Mar 30, 2026

About CF PharmTech

CF PharmTech, Inc. engages in research and development, production, and sale of respiratory drugs in the field of respiratory diseases in China. It offers Shufeimin, an azelastine hydrochloride and fluticasone propionate nasal spray; ChangQi, a budesonide inhalation suspension solution; ChangShu, a salbutamol sulfate inhalation solution; and piezoelectric mesh nebulizer, electric nasal cleaner, BFS hypertonic and physiological seawater nasal cleansing fluid products under the ChangShu name. The company also develops products for the treatment o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 574
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2652

Financial Performance

In 2024, CF PharmTech's revenue was 607.75 million, an increase of 9.23% compared to the previous year's 556.42 million. Earnings were 21.09 million, a decrease of -33.53%.

Financial numbers in CNY